ArticleCurrent medicinal chemistry2025
The Novel Prognostic Biomarker MAPK12 Promotes Migration, Proliferation, and Invasion in Head and Neck Squamous Cell Carcinoma.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe prognosis and survival rate of patients with head and neck squamous cell carcinoma (HNSCC) remain a serious public health concern. Therefore, elucidation of the underlying mechanisms responsible for the biological behavior of HNSCC is crucial for the development of effective treatment strategies. MATERIALS AND
methodsIn this study, we analyzed TCGA database and found that MAPK12 was overexpressed in tumor samples compared to normal samples, which was confirmed by microarray expression profiles, quantitative real-time polymerase chain reaction, and immunohistochemistry.
resultsCell functional experiments, including the cell counting kit-8 assay, wound healing test, and transwell assay, revealed that MAPK12 overexpression increased the proliferation, invasion, and migration of HNSCC cells. A correlation was observed between MAPK12 expression and patient survival in HNSCC across several clinicopathological variables, including disease grade and stage. Analysis of immune-related functions demonstrated that HNSCC patients with low MAPK12 expression had a more favorable tumor immune microenvironment and better immunological functions.
conclusionCollectively, our study identified for the first time that MAPK12 is upregulated in HNSCC, functioning as an oncogene, indicating a suppressive tumor immune microenvironment and poor prognosis since it could promote cancer cell proliferation, invasion, and migration. However, further studies are needed to gain a more comprehensive understanding of the role of MAPK12 in HNSCC and other tumor types.
Indexed as
Identifiers
42554336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.